Peptide LexiconAll compounds

Oritavancin: The Single-Dose Lipoglycopeptide Built on Vancomycin — What It Is and What Its Trials Showed

Oritavancin is a semisynthetic lipoglycopeptide antibiotic: the vancomycin core with an extra amino sugar and a chlorobiphenyl side chain added. One 1,200 mg infusion treats a skin infection, against 7 to 10 days of twice-daily vancomycin in its two trials of 1,987 adults. Two US products carry it, Orbactiv (2014, 3-hour infusion) and Kimyrsa (2021, 1-hour infusion).

FDA-approved (2014)Antibiotic (lipoglycopeptide)Single IV infusion

Caroline S · Published 2026-11-18

Length

Glycopeptide core with sugars and a lipophilic side chain; C86H97Cl3N10O26, molecular weight 1,793.1 (PubChem CID 16136912); diphosphate salt 1,989.09 (label)

Sequence

Not a simple linear sequence: the label's chemical name describes vancomycin with an added 3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl sugar and an N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl] group

Origin

Semisynthetic, derived from the glycopeptide scaffold of vancomycin (label chemical name). Orbactiv NDA 206334, approved 2014-08-06; Kimyrsa NDA 214155, approved 2021-03-12

Last reviewed

2026-11-18

What is it good for?

Treating acute bacterial skin and skin-structure infections in adults — cellulitis, wound infections and major abscesses — caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The whole course is one intravenous infusion.

Illustration: A clear glass IV bag with a pale green tint, hanging from a white metal stand against a deep green wall.
Illustration

What it is

Oritavancin is an antibiotic of the lipoglycopeptide class — vancomycin's peptide core, rebuilt. The Orbactiv label calls it "a semisynthetic lipoglycopeptide antibacterial drug," and its chemical name is written as vancomycin with two additions: an extra amino sugar (3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl) and a (4'-chloro-biphenyl-4-yl)methyl group on another sugar. That fat-loving biphenyl arm is the "lipo" in its class name.

Property Value Source
Formula (free) C86H97Cl3N10O26 PubChem CID 16136912
Molecular weight 1,793.1 (free) · 1,989.09 (diphosphate salt) PubChem · label
Orbactiv vial 400 mg oritavancin (three make the 1,200 mg dose) label
Kimyrsa vial 1,200 mg oritavancin, with hydroxypropyl-β-cyclodextrin label

The library's glycopeptide antibiotics entry places it with vancomycin, dalbavancin, the once-daily lipoglycopeptide telavancin and teicoplanin.

How it works

The label section on mechanism says only that oritavancin "is an antibacterial drug" and points to its microbiology section; this entry does not go beyond that. What the label does quantify is how it behaves in the body: about 85% protein-bound, a population volume of distribution of about 87.6 L ("extensively distributed into the tissues"), no metabolism seen in human liver microsome studies, linear kinetics up to 1,200 mg and a multi-exponential decline with a long terminal half-life. After one 1,200 mg dose in 297 trial patients, mean peak concentration was 138 µg/mL and total exposure (AUC 0–∞) 2,800 µg·h/mL.

That long tail is what allows one infusion to replace a week or more of treatment.

What the evidence shows

The approval rests on two identically designed, double-blind, non-inferiority trials — SOLO I and SOLO II — in 1,987 adults with cellulitis or erysipelas (40%), wound infections (29%) or major abscesses (31%). One 1,200 mg dose of oritavancin was compared with intravenous vancomycin every 12 hours for 7 to 10 days.

End point (48–72 h) Trial Oritavancin Vancomycin Difference (95% CI)
Early clinical response 1 391/475 (82.3%) 378/479 (78.9%) 3.4 (−1.6 to 8.4)
Early clinical response 2 403/503 (80.1%) 416/502 (82.9%) −2.7 (−7.5 to 2.0)
Lesion shrunk ≥20% 1 86.9% 82.9% 4.1 (−0.5 to 8.6)
Lesion shrunk ≥20% 2 85.9% 85.3% 0.6 (−3.7 to 5.0)

The SOLO I paper (NEJM 2014, PMID 24897083; funded by The Medicines Company) concluded that a single dose was non-inferior to the vancomycin course. Non-inferior means "not meaningfully worse within a set margin," not "better."

Kimyrsa, the second product, was approved on the basis of those trials plus a study of the faster infusion: 50 patients on each schedule reached almost identical exposure (AUC 0–72 of 1,460 and 1,470 µg·h/mL), with a higher peak on the 1-hour infusion (148 v 112 µg/mL).

The warning that surprises people is about blood tests, not bleeding. Oritavancin falsely prolongs the aPTT for up to 120 hours, PT and INR for up to 12 hours and ACT for up to 24 hours, so a patient on heparin may need a different test; with warfarin, the label calls for monitoring for bleeding. Other warnings: hypersensitivity (with care in people allergic to other glycopeptides), infusion reactions, C. difficile diarrhoea, and osteomyelitis needing alternative treatment. The common reactions (3% or more) were headache, nausea, vomiting, limb and skin abscesses, and diarrhoea.

What is not established on the label: use in children (a 118-child safety study is listed as completed on ClinicalTrials.gov), or for infections of implanted heart devices, which one registered study (NCT07013552) plans to test.

Where it stands

Two US products, both Melinta Therapeutics: Orbactiv (NDA 206334, approved 6 August 2014) and Kimyrsa (NDA 214155, approved 12 March 2021). Both are indicated only for acute bacterial skin and skin-structure infections in adults caused by susceptible Gram-positive bacteria, including MRSA and vancomycin-susceptible Enterococcus faecalis.

Sources opened 2026-11-18: Orbactiv label (openFDA, effective 2026-09-15: sections 1, 2, 5, 6, 11, 12.3, 14); Kimyrsa label (effective 2025-12-18: sections 2, 6, 11, 12.3); Drugs@FDA NDA 206334 and NDA 214155; PubChem CID 16136912; SOLO I, NEJM 2014 (PMID 24897083, abstract); ClinicalTrials.gov API v2 (21 records); PubMed E-utilities counts.

What the research shows

Treats skin infections in one dose

Two identical double-blind trials (SOLO I and II), 1,987 adults randomised, single 1,200 mg dose v vancomycin for 7–10 days: early response 82.3% v 78.9% and 80.1% v 82.9% (label Table 4)

Covers MRSA

Label indication names methicillin-susceptible and methicillin-resistant S. aureus among the listed organisms

A faster infusion works the same

Kimyrsa label: 1-hour v 3-hour infusion in 50 patients each, AUC 0–72 of 1,460 v 1,470 µg·h/mL; safety established from the Orbactiv trials plus one Kimyrsa study

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Orbactiv, NDA 206334 (2014-08-06; label effective 2026-09-15) and Kimyrsa, NDA 214155 (2021-03-12; label effective 2025-12-18), both Melinta Therapeutics (Drugs@FDA, openFDA).

Trials

ClinicalTrials.gov: 21 studies name oritavancin, including a completed paediatric safety study of 118 children (2026-11-18).

Published record

PubMed: 509 records for oritavancin, 9 tagged as randomised controlled trials (2026-11-18).

Frequently asked questions

What is oritavancin?

An antibiotic of the lipoglycopeptide class, made by chemically modifying the vancomycin scaffold. It kills Gram-positive bacteria, including MRSA, and is given as a single intravenous infusion for skin infections in adults.

Is oritavancin a peptide?

Its core is. Glycopeptide antibiotics such as vancomycin are built on a short chain of amino acids that is cross-linked and carries sugars. Oritavancin keeps that core and adds an extra amino sugar and a fatty chlorobiphenyl group, which is what 'lipo' refers to.

How is oritavancin given?

As one 1,200 mg intravenous infusion — the whole course. Orbactiv is infused over 3 hours and Kimyrsa over 1 hour; the labels warn that the two differ in strength, infusion time and preparation.

How did oritavancin compare with vancomycin?

In two identical trials, one dose of oritavancin was found non-inferior to 7 to 10 days of twice-daily vancomycin. Early response was 82.3% against 78.9% in one trial and 80.1% against 82.9% in the other.

Why does oritavancin affect blood-clotting tests?

The label describes it as test interference: results read falsely long — the aPTT for up to 120 hours. For patients who need clotting monitoring in that window, the label points to a test that does not depend on phospholipid, such as a chromogenic Factor Xa assay.

What are oritavancin's side effects?

The label's most common reactions, in 3% or more, are headache, nausea, vomiting, limb and skin abscesses, and diarrhoea. Its warnings include allergic reactions, infusion reactions, C. difficile diarrhoea, false clotting-test results and bone infection needing other treatment.